In 2015, the Clinical Trial Transformation Initiative (CTTI) recommended that trial sponsors consider fully or partially decentralized DCTs, defined as trials executed through telemedicine and mobile/local healthcare providers.
As with so many aspects of our daily lives, the impact of the COVID-19 pandemic on clinical trials was both widespread and monumental. Thousands of trials—an estimated 80% of non-COVID-19 trials
COVID-19 has changed the way healthcare is delivered and has rapidly affected the virtual care adoption and usage. To manage better their day-to-day routine care and control their diabetes and other chronic diseases symptoms.
The pandemic has turned lesser-known biopharmaceutical startups into household names, including vaccine developers Moderna and BioNTech. Now the company behind the AstraZeneca COVID-19 vaccine.
Glooko, the maker of a digital platform for managing diabetes and other chronic diseases, announced today a $30 million Series D funding round led by Health Catalyst Capital, Canaan Partners
One of the growing trends in the medtech industry is the rapid adoption of remote patient monitoring/telehealth. Glooko’s latest financing round is an example of the impact of the growing trend.
With a shift to virtual/decentralized clinical trials, the popularity of decentralized clinical trials (DCTs) skyrocketed following the nationwide lockdown last March.
While the far-reaching effects of COVID-19 have introduced the world to a “new normal,” the greatest impact has been in healthcare. In the long term, it has forever shaped the future of healthcare delivery, while its immediate effect has been on medical technology.
In an interview with Medtech Insight, Glooko CEO Russ Johannesson outlines the company’s growth opportunities, expansion plans beyond diabetes and financing plans.
A group of major CRO, life science, data analytics, publishing and healthcare companies, including Glooko, joined forces to release a pro bono research database to build up and integrate a central hub on the latest data out for COVID-19.